Personal Genome Project is looking for volunteers
Medicine becomes personalized under the influence of "big data"
As an example, they mention a long-term PGP study developed at Harvard University. It stands for "Personal Genomic Project" and is only consonant with the well-known cryptographic algorithm.
Within its framework, it is planned to sequence the personal genomes of one hundred thousand volunteers who are ready to give up their right to medical secrecy and privacy for the sake of science. Their complete genetic data, together with records from medical records, will be available for further research in the field of genetics and its clinical application in the form of personalized medicine.
One of the stages of the project provides for the work of researchers in Europe, where it will be supervised by the Association of the British Pharmaceutical Industry (ABPI). So far, volunteers are recruited from among residents of the USA, Canada and the UK. In the future, after the settlement of legal issues, it is also planned to cover South America and Asia.
Godfrey-Fossett said that the British PGP-UK initiative was one of the examples of improving the availability of medical information for scientific research:
"Analyzing and manipulating 'big data' also involves creating new, more focused databases that can be used independently and to identify implicit trends."
The specialist emphasized the importance of the international nature of the PGP initiative:
"The population is becoming more mobile, and geographical boundaries are becoming more blurred. Therefore, it is increasingly important for medical professionals to be able to access the data of visiting patients... The analysis of “big data" related to certain regions and population groups should improve the planning of medical care. It would help predict situations such as the rapid growth of the Gypsy community in Sheffield..."
Elistar Bus added that researchers can also benefit from data on failures. After all, a negative result is also of scientific value. For example, information about substances that have previously shown their inefficiency will help companies not to repeat other people's mistakes and avoid the cost of testing obviously unpromising components in drug development.
Using the potential of "big data" helps pharmaceutical companies reduce the time and money they spend on developing new drugs and at the stage of their introduction to the market. In combination with the development of genomic diagnostics, this has a positive effect on the healthcare system as a whole and contributes to the development of a separate area – personalized medicine.
Portal "Eternal youth" http://vechnayamolodost.ru28.11.2013